SecBot SecBot
SECBOTREPLAY Home › Report › BIIB

BIIB · Biogen and Eisai announced that China's NMPA approved the subcutaneous…

Biogen Inc. · PRESS-RELEASE filed Sep 3, 2026 at 00:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Sep 3, 2026 at 00:00 ET

Biogen and Eisai announced that China's NMPA approved the subcutaneous autoinjector formulation of LEQEMBI (lecanemab) for early Alzheimer's disease. This is the second country globally to approve the SC formulation, expanding LEQEMBI's market in China, which Eisai estimates had 17 million early AD patients in 2024. The approval removes a key barrier to treatment adoption by enabling at-home, once-weekly self-administration versus bi-weekly IV infusions in a hospital.

  • China NMPA approved LEQEMBI subcutaneous autoinjector (SC-AI) for early Alzheimer's disease.
  • SC-AI enables once-weekly at-home self-administration (500 mg as two 250 mg injections) vs. bi-weekly IV in hospital.
  • China had an estimated 17 million MCI or mild AD dementia patients in 2024, per Eisai.
  • Launch planned during Eisai's FY2026 (ending March 31, 2027).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access